These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35337940)

  • 21. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.
    van Rijn CJM; Vlaming KE; Bem RA; Dekker RJ; Poortinga A; Breit T; van Leeuwen S; Ensink WA; van Wijnbergen K; van Hamme JL; Bonn D; Geijtenbeek TBH
    Sci Rep; 2023 May; 13(1):8851. PubMed ID: 37258559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory Capability.
    Lei J; Qi S; Yu X; Gao X; Yang K; Zhang X; Cheng M; Bai B; Feng Y; Lu M; Wang Y; Li H; Yu G
    Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202318515. PubMed ID: 38320193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in delivering RNA-based therapeutics to mitochondria.
    Yamada Y; Ishizuka S; Arai M; Maruyama M; Harashima H
    Expert Opin Biol Ther; 2022 Sep; 22(9):1209-1219. PubMed ID: 35543589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy.
    Jolly KJ; Zhang F
    Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics.
    Mukai H; Ogawa K; Kato N; Kawakami S
    Drug Metab Pharmacokinet; 2022 Jun; 44():100450. PubMed ID: 35381574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
    Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
    Front Immunol; 2022; 13():856657. PubMed ID: 35401503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
    Andries J; Viranaicken W; Cordonin C; Herrscher C; Planesse C; Roquebert B; Lagrange-Xelot M; El-Kalamouni C; Meilhac O; Mavingui P; Couret D; Gadea G; Despres P
    Sci Rep; 2022 Apr; 12(1):5999. PubMed ID: 35397679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nano delivery systems and applications of mRNA.
    Li M; Li Y; Li S; Jia L; Wang H; Li M; Deng J; Zhu A; Ma L; Li W; Yu P; Zhu T
    Eur J Med Chem; 2022 Jan; 227():113910. PubMed ID: 34689071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
    Kang SH; Kim MY; Cho MY; Baik SK
    J Korean Med Sci; 2022 Apr; 37(15):e116. PubMed ID: 35437965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.
    Labouta HI; Langer R; Cullis PR; Merkel OM; Prausnitz MR; Gomaa Y; Nogueira SS; Kumeria T
    Drug Deliv Transl Res; 2022 Nov; 12(11):2581-2588. PubMed ID: 35290656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging advances in delivery systems for mRNA cancer vaccines.
    Jiang Z; Xu Y; Du G; Sun X
    J Control Release; 2024 Jun; 370():287-301. PubMed ID: 38679162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines.
    Wu Y; Yu S; de Lázaro I
    Nanoscale; 2024 Apr; 16(14):6820-6836. PubMed ID: 38502114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer.
    Ji A; Xu M; Pan Y; Diao L; Ma L; Qian L; Cheng J; Liu M
    Pharm Res; 2023 Jan; 40(1):265-279. PubMed ID: 36451070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 39. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
    Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
    Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.